We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.055 | -2.40% | 2.24 | 2.20 | 2.28 | 2.28 | 2.21 | 2.21 | 734,558 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.00 | 7.6M |
From Apr 2019 to Apr 2024
TIDMIMM
RNS Number : 0613R
Immupharma PLC
19 September 2017
FOR IMMEDIATE RELEASE 19 SEPTEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
NOTIFICATION OF INTERIM RESULTS
Date: 27 September 2017
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, confirms that it will be announcing its Interim results for the six months ended 30 June 2017 on Wednesday 27 September 2017.
-Ends-
Hot Features
Premium
For further information please
contact:
+ 44 (0) 20
ImmuPharma plc (www.immupharma.org) 7152 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721
Twitter: @immupharma 413496
Northland Capital Partners Limited
(Joint Broker)
Patrick Claridge, David Hignell,
Jamie Spotswood, Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORXVLFFDKFLBBQ
(END) Dow Jones Newswires
September 19, 2017 02:01 ET (06:01 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
